OBJECTIVES: The aim of this study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD) in community-living individuals. BACKGROUND: Fetuin-A is a hepatic secretory protein that inhibits arterial calcium deposition in vitro. Lower fetuin-A levels are associated with arterial calcification and death in end-stage renal disease populations. The association of fetuin-A with subclinical CVD in the general population is unknown. METHODS: Among 1,375 community-living individuals without prevalent clinical CVD, we measured plasma fetuin-A concentrations. Peripheral arterial disease (PAD) was defined by ankle brachial index <0.90, coronary artery calcification (CAC) was measured by computed tomography, and common and internal intima-media thickness (cIMT) were measured by carotid ultrasound. PAD was measured concurrent with fetuin-A, and CAC and cIMT were measured 4.6 years (mean) later. RESULTS: Mean age was 70 ± 11 years, and 64% were women. Fetuin-A levels were inversely associated with CAC severity. When evaluated as CAC categories (0, 1 to 100, 101 to 300, >300) with ordinal logistic regression, each SD higher fetuin-A was associated with 31% lower odds of CAC severity (proportional odds ratio: 0.69; 95% confidence interval: 0.46 to 0.92; p = 0.008) in models adjusted for demographic data, lifestyle factors, traditional CVD risk factors, and kidney function. In contrast, no association of fetuin-A was observed with PAD or high common or internal cIMT in adjusted models. CONCLUSIONS: Lower fetuin-A levels are independently associated with greater CAC severity but not PAD or cIMT. If confirmed, fetuin-A might mark calcium deposition within the vasculature but not atherosclerosis per se.
OBJECTIVES: The aim of this study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD) in community-living individuals. BACKGROUND:Fetuin-A is a hepatic secretory protein that inhibits arterial calcium deposition in vitro. Lower fetuin-A levels are associated with arterial calcification and death in end-stage renal disease populations. The association of fetuin-A with subclinical CVD in the general population is unknown. METHODS: Among 1,375 community-living individuals without prevalent clinical CVD, we measured plasma fetuin-A concentrations. Peripheral arterial disease (PAD) was defined by ankle brachial index <0.90, coronary artery calcification (CAC) was measured by computed tomography, and common and internal intima-media thickness (cIMT) were measured by carotid ultrasound. PAD was measured concurrent with fetuin-A, and CAC and cIMT were measured 4.6 years (mean) later. RESULTS: Mean age was 70 ± 11 years, and 64% were women. Fetuin-A levels were inversely associated with CAC severity. When evaluated as CAC categories (0, 1 to 100, 101 to 300, >300) with ordinal logistic regression, each SD higher fetuin-A was associated with 31% lower odds of CAC severity (proportional odds ratio: 0.69; 95% confidence interval: 0.46 to 0.92; p = 0.008) in models adjusted for demographic data, lifestyle factors, traditional CVD risk factors, and kidney function. In contrast, no association of fetuin-A was observed with PAD or high common or internal cIMT in adjusted models. CONCLUSIONS: Lower fetuin-A levels are independently associated with greater CAC severity but not PAD or cIMT. If confirmed, fetuin-A might mark calcium deposition within the vasculature but not atherosclerosis per se.
Authors: Markus Ketteler; Philipp Bongartz; Ralf Westenfeld; Joachim Ernst Wildberger; Andreas Horst Mahnken; Roland Böhm; Thomas Metzger; Christoph Wanner; Willi Jahnen-Dechent; Jürgen Floege Journal: Lancet Date: 2003-03-08 Impact factor: 79.321
Authors: Kenneth J Mukamal; Richard A Kronmal; Murray A Mittleman; Daniel H O'Leary; Joseph F Polak; Mary Cushman; David S Siscovick Journal: Arterioscler Thromb Vasc Biol Date: 2003-10-16 Impact factor: 8.311
Authors: T Filardi; F Panimolle; C Tiberti; C Crescioli; A Lenzi; N Pallotta; S Morano Journal: J Endocrinol Invest Date: 2020-04-30 Impact factor: 4.256
Authors: Monik C Jiménez; Qi Sun; Markus Schürks; Frank B Hu; Joann E Manson; Kathryn M Rexrode Journal: Clin Chem Date: 2013-10-29 Impact factor: 8.327
Authors: Sarah A Aroner; Kenneth J Mukamal; David E St-Jules; Matthew J Budoff; Ronit Katz; Michael H Criqui; Matthew A Allison; Ian H de Boer; David S Siscovick; Joachim H Ix; Majken K Jensen Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: Gail A Laughlin; Kevin M Cummins; Christina L Wassel; Lori B Daniels; Joachim H Ix Journal: J Am Coll Cardiol Date: 2012-05-08 Impact factor: 24.094
Authors: Gail A Laughlin; Linda K McEvoy; Elizabeth Barrett-Connor; Lori B Daniels; Joachim H Ix Journal: Clin Endocrinol (Oxf) Date: 2014-01-07 Impact factor: 3.478
Authors: Simerjot Kaur Jassal; Michel Chonchol; Gail A Laughlin; Kevin M Cummins; Gerard Smits; Caroline K Kramer; Joachim H Ix; Elizabeth Barrett-Connor Journal: Am J Cardiol Date: 2012-08-08 Impact factor: 2.778
Authors: Yashu Liu; Toufan Parman; Bridget Schneider; Benben Song; Amit K Galande; Dave Anderson; Jon Mirsalis Journal: J Proteome Res Date: 2013-03-28 Impact factor: 4.466
Authors: Gail A Laughlin; Elizabeth Barrett-Connor; Kevin M Cummins; Lori B Daniels; Christina L Wassel; Joachim H Ix Journal: Diabetes Care Date: 2013-01-11 Impact factor: 19.112